Dr. Nirali N. Shah
Claim this profileNational Institutes of Health, Clinical Center
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
13 reported clinical trials
19 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
CD19 positive
CD33 positive
CD22 positive
2Acute Lymphoblastic Leukemia
CD19 positive
CD22 positive
CD19 negative
Affiliated Hospitals
Clinical Trials Nirali N. Shah is currently running
CAR T-Cell Therapy
for Acute Lymphoblastic Leukemia
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses. Objective: To test chimeric antigen receptor (CAR) therapy. CARs are genetically modified cells created from each patient s own blood cells. his trial will use a new type of CAR T-cell that is targeting both CD19 and CD22 at the same time. CD19 and CD22 are proteins found on the surface of most types of ALL. Eligibility: People aged 3 to 39 with ALL or related B-cell lymphoma that has not been cured by standard therapy. Design: Participants will be screened. This will include: Physical exam Blood and urine tests Tests of their lung and heart function Imaging scans Bone marrow biopsy. A large needle will be inserted into the body to draw some tissues from the interior of a bone. Lumbar puncture. A needle will be inserted into the lower back to draw fluid from the area around the spinal cord. Participants will undergo apheresis. Their blood will circulate through a machine that separates blood into different parts. The portion containing T cells will be collected; the remaining cells and fluids will be returned to the body. The T cells will be changed in a laboratory to make them better at fighting cancer cells. Participants will receive chemotherapy starting 4 or 5 days before the CAR treatment. Participants will be admitted to the hospital. Their own modified T cells will be returned to their body. Participants will visit the clinic 2 times a week for 28 days after treatment. Follow-up will continue for 15 years....
Recruiting1 award Phase 1 & 2
Inotuzumab Ozogamicin
for Leukemia and Lymphoma
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Recruiting1 award Phase 210 criteria
More about Nirali N. Shah
Clinical Trial Related8 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Nirali N. Shah has experience with
- Fludarabine
- Cyclophosphamide
- VOR33
- NGS Testing
- Busulfan (Busulfex)
- Reduced-intensity Hematopoietic Stem Cell
Breakdown of trials Nirali N. Shah has run
T-Lymphoblastic Leukemia/Lymphoma
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nirali N. Shah specialize in?
Nirali N. Shah focuses on T-Lymphoblastic Leukemia/Lymphoma and Acute Lymphoblastic Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved CD19 positive patients, or patients who are CD33 positive.
Is Nirali N. Shah currently recruiting for clinical trials?
Yes, Nirali N. Shah is currently recruiting for 8 clinical trials in Bethesda Maryland. If you're interested in participating, you should apply.
Are there any treatments that Nirali N. Shah has studied deeply?
Yes, Nirali N. Shah has studied treatments such as Fludarabine, Cyclophosphamide, VOR33.
What is the best way to schedule an appointment with Nirali N. Shah?
Apply for one of the trials that Nirali N. Shah is conducting.
What is the office address of Nirali N. Shah?
The office of Nirali N. Shah is located at: National Institutes of Health, Clinical Center, Bethesda, Maryland 20892 United States. This is the address for their practice at the National Institutes of Health, Clinical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.